Valuation: Autolus Therapeutics plc

Market Cap 474M 423M 394M 358M 675M 45.63B 680M 4.76B 1.85B 23.29B 1.78B 1.74B 74.85B P/E 2026 *
-2.21x
P/E 2027 * -2.61x
Enterprise Value 318M 283M 264M 240M 453M 30.6B 456M 3.19B 1.24B 15.62B 1.19B 1.17B 50.2B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 2.06x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+1.97%
1 week-2.69%
Current month-6.70%
1 month-14.22%
3 months+11.04%
6 months+30.22%
Current year-9.05%
1 week 1.75
Extreme 1.75
1.99
1 month 1.75
Extreme 1.75
2.23
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2014-08-31
Chief Executive Officer 61 2016-02-29
Director of Finance/CFO 56 2023-08-06
Director TitleAgeSince
Chairman 61 2014-09-30
Director/Board Member 78 2014-07-31
Director/Board Member 71 2018-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Sell

Executive/Senior Manager

-6,713 0.0025%
6/29/26 Free

Director

79,167 0.0477%
3/18/26 Other

Chief Executive Officer

6,917,877 4.1641%
Change 5-day change 1-year change 3-year change Capi.($)
+2.53%-2.69%+16.03%-21.65% 474M
+0.62%-3.06%+35.92%+112.12% 1,019B
-1.10%-6.93%+34.51%+61.06% 617B
+0.36%-1.01%+14.51%+78.77% 464B
-3.16%-5.87%+57.61%+35.09% 356B
+0.93%-1.83%+20.98%+41.43% 333B
+0.12%-4.05%+10.09%+33.53% 267B
-0.89%-5.83%-7.56%+7.91% 244B
-0.00%-3.74%+36.84%+51.83% 218B
-0.37%-5.42%+26.75%+92.72% 179B
Average -0.23%-3.59%+24.57%+49.28% 369.77B
Weighted average by Cap. -0.31%-3.54%+28.62%+68.58%

Financials

2026 *2027 *
Net sales 150M 134M 124M 113M 213M 14.43B 215M 1.5B 585M 7.36B 562M 550M 23.67B 192M 172M 160M 146M 274M 18.53B 276M 1.93B 752M 9.46B 722M 707M 30.4B
Net income -219M -195M -182M -166M -312M -21.08B -314M -2.2B -855M -10.76B -822M -804M -34.58B -185M -165M -154M -140M -264M -17.86B -266M -1.86B -724M -9.11B -696M -681M -29.29B
Net Debt -156M -139M -130M -118M -222M -15.03B -224M -1.57B -610M -7.67B -586M -573M -24.65B -77.38M -69.03M -64.31M -58.52M -110M -7.45B -111M -777M -302M -3.8B -290M -284M -12.23B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
26-10-05 $1.825 +2.53% 1,274,949
26-10-02 $1.780 -3.78% 1,811,774
26-10-01 $1.850 -4.64% 1,458,882
26-09-30 $1.940 +4.30% 1,159,393
26-09-29 $1.860 0.00% 1,770,892
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.780USD
Average target price
8.725USD
Spread / Average Target
+390.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock